INS and metabolic syndrome: Although during hospitalization period we treated him with intensive insulin therapy for T2DM, after the improvement of acute pancreatitis, he was taking 400 mg/day of bezafibrate and 1800 mg/day of ethyl icosapentate for the treatment of dyslipidemia and 30 mg/day of mitiglinide, 0.6 mg/day of voglibose, 1500 mg/day of metformin and insulin therapy (4 units of glargine) for T2DM at discharge.